American Regent introduces FDA-approved Vasopressin Injection, USP
MELVILLE, N.Y., Feb. 3, 2022 /PRNewswire/ -- American Regent, Inc. announces the introduction and availability of FDA-approved Vasopressin Injection, USP. Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
"We are pleased to provide this critical medication for patients who need it. The approval of Vasopressin represents our commitment to providing the market with access to competitively priced treatment options," stated Joann Gioia, Vice President, Chief Commercial Officer at American Regent, Inc.
This product is available for immediate shipment. Customers can order Vasopressin Injection, USP through their wholesaler/distributor, or by contacting our Customer Support Group at 1-800-645-1706.
Vasopressin Injection is supplied as follows:
See the following Important Safety Information, in addition to the product's Full Prescribing Information.
For additional information, please visit www.americanregent.com.
Vasopressin Injection, USP
INDICATIONS AND USAGE
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
The following additional adverse reactions were identified:
Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding
USE IN SPECIFIC POPULATIONS
Pediatric Use: Safety and effectiveness have not been established.
Geriatric Use: Dose selection for an elderly patient should be cautious.
For additional safety information, please see Full Prescribing Information.
You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236, or to the FDA by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088.
You are encouraged to report adverse drug events (ADEs) to American Regent:
ADEs may also be reported to the FDA:
For medical information outside of normal business hours,
About American Regent
American Regent is committed to US-based manufacturing. To that end, over the last several years, we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.
Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.
For more information, please visit www.americanregent.com.
About Daiichi Sankyo Group
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group.
For more information on Daiichi Sankyo, Inc., please visit www.dsi.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/american-regent-introduces-fda-approved-vasopressin-injection-usp-301474869.html
SOURCE American Regent, Inc.